Synthetic Biologics Inc (NYSE:SYN) has been given a consensus broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and four have assigned a strong buy recommendation to the company.
Brokerages have set a 1-year consensus price target of $7.25 for the company and are forecasting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned Synthetic Biologics an industry rank of 111 out of 265 based on the ratings given to its competitors.
A number of analysts recently commented on SYN shares. Zacks Investment Research lowered Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Thursday, July 7th. FBR & Co reaffirmed a “buy” rating on shares of Synthetic Biologics in a research note on Friday, August 5th. Griffin Securities set a $5.80 price target on Synthetic Biologics and gave the stock a “buy” rating in a research note on Wednesday, August 31st. Finally, BTIG Research started coverage on Synthetic Biologics in a research note on Thursday, August 25th. They issued a “buy” rating and a $5.00 price target for the company.
Synthetic Biologics (NYSE:SYN) traded down 2.1902% during mid-day trading on Friday, hitting $1.5943. 166,732 shares of the stock traded hands. Synthetic Biologics has a 52-week low of $0.93 and a 52-week high of $3.09. The firm’s market cap is $145.51 million. The firm’s 50-day moving average is $1.69 and its 200 day moving average is $1.93.
Synthetic Biologics (NYSE:SYN) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. Equities analysts predict that Synthetic Biologics will post ($0.39) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in SYN. Vanguard Group Inc. raised its position in shares of Synthetic Biologics by 10.5% in the second quarter. Vanguard Group Inc. now owns 2,761,194 shares of the company’s stock valued at $4,970,000 after buying an additional 262,551 shares in the last quarter. BlackRock Investment Management LLC raised its position in shares of Synthetic Biologics by 2,517.2% in the second quarter. BlackRock Investment Management LLC now owns 282,158 shares of the company’s stock valued at $508,000 after buying an additional 271,377 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Synthetic Biologics by 1,271.8% in the second quarter. BlackRock Fund Advisors now owns 1,967,983 shares of the company’s stock valued at $3,542,000 after buying an additional 1,824,521 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Synthetic Biologics by 53.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,779,542 shares of the company’s stock valued at $3,203,000 after buying an additional 622,316 shares in the last quarter. Finally, Teachers Advisors Inc. purchased a new position in shares of Synthetic Biologics during the second quarter valued at approximately $216,000.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.